LEAP-012 TRIAL IN PROGRESS: PEMBROLIZUMAB, LENVATINIB, AND TRANSARTERIAL CHEMOEMBOLIZATION COMBINATION THERAPY FOR INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA NOT AMENABLE TO CURATIVE TREATMENT

被引：0
|
作者：
Vogel, Arndt [1 ]
Llovet, Josep M. [2 ]
El-Khoueiry, Anthony B. [3 ]
Madoff, David C. [4 ,5 ]
Finn, Richard [6 ]
Ogasawara, Sadahisa [7 ]
Ren, Zhenggang [8 ]
Mody, Kalgi [9 ]
Li, Jerry J. [10 ]
Siegel, Abby B. [10 ]
Dubrovsky, Leonid [10 ]
Kudo, Masatoshi [11 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[4] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[5] Yale New Haven Hlth, Smilow Canc Hosp, New Haven, CT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Chiba Univ, Grad Sch Med, Chiba, Japan
[8] Fudan Univ, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China
[9] Eisai Inc, Woodcliff Lake, NJ USA
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Higashiosaka, Osaka, Japan
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1156
引用
收藏
页码：697A / 698A
页数：2
相关论文
共 50 条
  • [1] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet, J. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Madoff, D. C.
    Finn, R. S.
    Ogasawara, S.
    Ren, Z.
    Mody, K.
    Li, J. Jing
    Siegel, A. B.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S703
  • [2] Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (04) : 405 - 412
  • [3] Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
    Josep M. Llovet
    Arndt Vogel
    David C. Madoff
    Richard S. Finn
    Sadahisa Ogasawara
    Zhenggang Ren
    Kalgi Mody
    Jerry J. Li
    Abby B. Siegel
    Leonid Dubrovsky
    Masatoshi Kudo
    CardioVascular and Interventional Radiology, 2022, 45 : 405 - 412
  • [4] LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Ogasawara, S.
    Llovet, J.
    El-Khoueiry, A.
    Vogel, A.
    Madoff, D.
    Finn, R.
    Ren, Z.
    Modi, K.
    Li, J.
    Siegel, A.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S124 - S125
  • [6] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
  • [7] Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024,
  • [8] Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Zhou, Qunfang
    Tuo, Fei
    Li, Ruixia
    Wang, Xiaohui
    Wang, Juncheng
    Huang, Zhimei
    Chen, Minshan
    Huang, Jinhua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
    Hatanaka, Takeshi
    Yata, Yutaka
    Naganuma, Atsushi
    Kakizaki, Satoru
    CANCERS, 2023, 15 (06)
  • [10] Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma
    Chen, Shuling
    Jin, Huilin
    Dai, Zihao
    Wei, Mengchao
    Xiao, Han
    Su, Tianhong
    Li, Bin
    Liu, Xin
    Wang, Yu
    Li, Jiaping
    Shen, Shunli
    Zhou, Qi
    Peng, Baogang
    Peng, Zhenwei
    Peng, Sui
    CANCER MEDICINE, 2019, 8 (04): : 1530 - 1539
12345